natgillin/translations-raw huggingface dataset:
Powder: 4 mg;
Prašek: 4 mg;
powder: 4 mg; solvent: 1.5 ml
prašek: 4 mg; vehikel: 1.5 ml
powder: 4 mg; solvent: 5 ml
prašek: 4 mg; vehikel: 5 ml
Powder: 40 mg; solvent: 2 ml
prašek: 40 mg; vehikel: 2 ml
Powder: 400 mg
Prašek: 400 mg
powder: 5 g gel: 50 g
prašek: 5 g gel: 50 g
Powder: 5 mg
Prašek: 5 mg
powder: 5 mg (250 KIU); (50
prašek: 5 mg (250
powder: 5 µg;
prašek: 5 µg;
powder: 5.8 mg;
Prašek: 5,8 mg
powder: 500 IU
prašek: 500 IU;
Powder: 500 IU + Solvent: 2.5 ml (200 IU/ml)
Prašek: 500 i.e. + Vehikel: 2,5 ml (200 i.e./ml)
Powder: 500 IU efmoroctocog alfa (approx.
Prašek: 500 i.e. efmoroktokoga alfa (pribl.
Powder: 500 IU eftrenonacog alfa (approx.
Prašek: 500 i.e. eftrenonakoga alfa (pribl.
Powder: 500 IU powder in 8 ml type 1 glass vial, closed with coated bromobutyl stopper and sealed with aluminium flip-off cap
Prašek: 500 i.e. prašek v 8-ml viali iz stekla tipa 1, zaprti z obloženim bromobutilnim zamaškom in zaščiteni z aluminijasto snemljivo zaporko
Powder: 500 IU;
Prašek: 500 i.e.;
powder: 500 IU;
prašek: 500 IU;
Powder: 500 µg (500 µg/ml)
Prašek: 500 µg (500 µg/ml)
Powder: 60 mg; solvent: 2 ml
prašek: 60 mg; vehikel: 2 ml
powder: 7 mg; solvent: 1.5 ml
prašek: 7 mg; vehikel: 1.5 ml
powder: 7.5 mg; solvent: 5 ml (1.5 mg/ml)
vehikel: 5 ml (1,5
powder: 75 IU;
prašek: 75 i.e.;
powder: 75 mg; solvent: 2 ml
prašek: 75 mg; vehikel: 2 ml
Powder: 750 IU efmoroctocog alfa (approx.
Prašek: 750 i.e. efmoroktokoga alfa (pribl.
powder: 8 mg (400 KIU); (50
prašek: 8 mg (400
Powder: 80 mg Solvent: 4ml
prašek: 80 mg vehikel: 4 ml
powder: 80 µg;
uporabo
Powder: Contains sucrose, trometamol, hydrochloric acid
Prašek: vsebuje saharozo, trometamol, klorovodikovo kislino.
Powder: dextran, sucrose, sorbitol (see also section 2, Rotarix contains sucrose and sorbitol), amino acids, Dulbecco’s Modified Eagle Medium (DMEM)
Prašek: dekstran, saharoza, sorbitol, (glejte tudi poglavje 2, Cepivo Rotarix vsebuje saharozo in sorbitol), aminokisline, Dulbekov spremenjeni nujni medij (DMEM – »Dulbecco’s Modified Eagle Medium«)
Powder: disodium phosphate dihydrate, sodium dihydrogen phosphate monohydrate, methionine, polysorbate 20, sucrose.
Prašek: natrijev hidrogenfosfat dihidrat, natrijev dihidrogenfosfat monohidrat, metionin, polisorbat 20, saharoza.
Powder: disodium phosphate; anhydrous, sodium dihydrogen phosphate dihydrate; sucrose and polysorbate 80.
Prašek: natrijev hidrogenfosfat, brezvodni; natrijev dihidrogenfosfat dihidrat, saharoza in polisorbat 80
Powder: Do not store above 30 ºC
Prašek: Shranjujte pri temperaturi do 30 °C
Powder: Do not store above 30C
Prašek: Shranjujte pri temperaturi do 30 °C
Powder: Do not store above 30C.
Prašek: Shranjujte pri temperaturi do 30 °C.
powder: glass container; solvent: oral applicator (glass)
prašek: stekleni vsebnik; vehikel: peroralni aplikator (steklo)
Powder: glycine disodium hydrogen phosphate heptahydrate sodium dihydrogen phosphate dihydrate
Prašek: glicin natrijev hidrogenfosfat heptahidrat natrijev dihidrogenfosfat dihidrat
Powder: Macrogol 4000
Prašek:
Powder: magnesium chloride sodium hydroxide Solvent: mannitol (E 421) water for injections
Prašek: magnezijev klorid natrijev hidroksid Vehikel: manitol (E 421) voda za injekcije
Powder: magnesium chloride, sodium hydroxide Solvent: mannitol, water for injections
Prašek: magnezijev klorid, natrijev hidroksid Vehikel: manitol, voda za injekcije
Powder: Mannitol
Prašek: manitol
Powder: Sodium chloride Sucrose Histidine.
Prašek: natrijev klorid saharoza histidin
Powder: Sodium chloride, L-histidine, sucrose, polysorbate 80, L-methionine, calcium chloride dihydrate, sodium hydroxide, hydrochloric acid
Prašek: natrijev klorid, L-histidin, saharoza, polisorbat 80, L-metionin, kalcijev klorid dihidrat, natrijev hidroksid, klorovodikova kislina.
Powder: Sodium chloride, sucrose, polysorbate 20, L-histidine, hydrochloric acid (for pH- adjustment), sodium hydroxide (for pH-adjustment)
Prašek: natrijev klorid, saharoza, polisorbat 20, L-histidin, klorovodikova kislina (za prilagoditev pH), natrijev hidroksid (za prilagoditev pH)
Powder: Sodium dihydrogen phosphate dihydrate, disodium phosphate dodecahydrate, human serum albumin
Prašek: natrijev dihidrogenfosfat dihidrat, natrijev hidrogenfosfat dodekahidrat, humani serumski albumin
Powder: sodium hyaluronate, egg phospholipids, sodium dihydrogen phosphate anhydrous, disodium phosphate anhydrous.
Prašek: natrijev hialuronat, jajčni fosfolipidi, brezvodni natrijev dihidrogenfosfat, brezvodni dinatrijev fosfat
Powder: Sucrose
Prašek: saharoza
Powder: sucrose, disodium phosphate dihydrate, sodium dihydrogen phosphate monohydrate, methionine, polysorbate 20, concentrated phosphoric acid and sodium hydroxide.
Prašek: saharoza, natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat dihidrat, metionin, polisorbat 20, koncentrirana fosforjeva kislina in natrijev hidroksid.
Powder: sucrose, histidine, histidine hydrochloride monohydrate, polysorbate 80.
Prašek: saharoza, histidin, histidinijev klorid monohidrat, polisorbat 80.
Powder: sucrose, L- histidine, mannitol, polysorbate 20, sodium hydroxide, hydrochloric acid
Prašek: saharoza, L-histidin, manitol polisorbat 20, natrijev hidroksid, klorovodikova kislina
Powder: sucrose, sorbitol
Prašek: saharoza, sorbitol
powder: vial
prašek: viala (steklo)
Powder: vial (glass)
prašek:
Powder: vial (glass)
prašek: viala (steklena);
Powder: vial (glass)
Prašek: viala (steklo)
Powder: vial (glass) Solution: vial (glass)
Prašek: viala (steklena) Raztopina: viala (steklena)
Powder: vial (glass) Solvent: ampoule (glass)
prašek: viala (steklena);
Powder: vial (glass) Solvent: ampoule (glass)
prašek: viala (steklena); topilo: ampula (steklena)
Powder: vial (glass) Solvent: ampoule (glass)
prašek: viala (steklo) vehikel: ampula (steklo)
Powder: vial (glass) Solvent: ampoule (PE)
Prašek: viala (steklena) Vehikel: ampula (PE)
Powder: vial (glass) Solvent: pre- filled syringe (glass)
prašek: viala (steklena) vehikel: napolnjena injekcijska brizga (steklena)
Powder: vial (glass) Solvent: pre-filled syringe (glass)
prašek: viala (steklo); vehikel: napolnjena injekcijska brizga
Powder: vial (glass) Solvent: pre-filled syringe (glass)
vehikel: napolnjena injekcijska brizga (steklo)
powder: vial (glass) solvent: vial (glass)
prašek: viala (steklena) vehikel: viala (steklena)
Powder: vial (glass) Solvent: vial (glass)
Prašek: viala (steklo) vehikel: viala (steklo)
powder: vial (glass), solvent: pre-filled syringe (glass)
prašek: viala (steklo), vehikel: napolnjena injekcijska brizga (steklo)
powder: vial (glass);
prašek: viala
powder: vial (glass);
prašek: viala (steklena) vehikel: viala (steklena)
Powder: vial (glass);
prašek: viala (steklo)
powder: vial (glass);
prašek: viala (steklo);
powder: vial (glass);
prašek: viala (steklo); vehikel:
powder: vial (glass);
prašek: viala (steklo); vehikel: ampula (steklo)
powder: vial (glass);
prašek: viala (steklo); vehikel: viala (steklo)
Powder: vial (glass);
raztopino za injiciranje
powder: vial (glass); diluent: bottle (glass)
prašek: viala (steklo); vehikel: steklenicah iz stekla
powder: vial (glass); gel: bottle (glass)
prašek: viala (steklo); gel: steklenica (steklo)
Powder: vial (glass); solvent:
Prašek: viala (steklo)
powder: vial (glass); solvent: ampoule (glass)
prašek: viala (steklena); vehikel: ampula (steklena)
Powder: vial (glass); solvent: pre-
Vehikel: Napolnjena brizga (steklo) igli
Powder: vial (glass); Solvent: pre- filled syringe (glass)
prašek: viala (steklo); vehikel: napolnjena injekcijska brizga (steklo)
Powder: vial (glass); Solvent: pre-filed syringe (glass)
prašek: viala (steklo)
powder: vial (glass); solvent: pre-filled syringe
prašek: viala (steklo); vehikel: napolnjena injekcijska brizga (steklo)
Powder: vial (glass); solvent: pre-filled syringe (glass)
Prašek: (steklena) viala; vehikel: (steklena) napolnjena injekcijska brizga
Powder: vial (glass); solvent: pre-filled syringe (glass)
Prašek: viala (steklo) Vehikel: napolnjena injekcijska brizga (steklo)
Powder: vial (glass); solvent: pre-filled syringe (glass)
Prašek: viala (steklo); Vehikel: napolnjena injekcijska brizga (steklo)
Powder: vial (glass); solvent: pre-filled syringe(glass)
(steklo); vehikel: napolnjena injekcijska brizga (steklo)
powder: vial (glass); solvent: syringe (glass)
prašek: viala (steklo);
powder: vial (glass); solvent: vial (glass)
prašek : viala (steklo); vehikel: viala (steklo)
Powder: vial (glass); Solvent: vial (glass)
Prašek: viala (steklena); Vehikel: viala (steklena)
powder: vial (glass); solvent: vial (glass)
prašek: viala (steklo); vehikel: viala (steklo)
powder: vial (glass); solvent: vial (glass); matrix: blister
prašek: viala (steklo); vehikel: viala (steklo); ogrodje: pretisni omot prašek: viala (steklo); vehikel: viala (steklo); ogrodje: pretisni omot
Powder: Vial (type I glass) closed with a rubber stopper (butyl) and a light-blue flip-off cap (aluminium and plastic).
Prašek: Viala (steklo tipa I), zaprta z gumijastim zamaškom (butil) in svetlomodro prekrivno zaporko (aluminij in plastika).
Powder: white to off-white friable powder.
Prašek: bel do belkast drobljiv prašek.
Powder: white to off-white lyophilisate Solvent: clear and colourless solution
Vehikel: bistra in brezbarvna raztopina
Powder: white to off-white lyophilised pellet.
Prašek: bele do sivo bele liofilizirane pelete.
Powder: white to off-white Solvent: clear solution
Prašek: bel do belkast prašek Vehikel: bistra raztopina
powder:10 mg; solvent: 1.5 ml
prašek:10 mg; vehikel: 1,5 ml
POWER 1 and POWER 2 pooled data
Združeni podatki preskušanj POWER 1 in POWER 2
Power frequency magnetic fields should be at levels characteristic of a typical location in a typical commercial or hospital environment.
Frekvenčna moč magnetnih polj naj bo na stopnji, značilni za poslovna ali bolnišnična okolja.
PP (per protocol) Population
PP populacija (bolniki, zdravljeni v skladu s protokolom)
PP (Polypropylene) or PVC (Polyvinyl chloride) bags should be used for administration preparation.
Za pripravo na dajanje uporabite PP (polipropilenske) ali PVC (polivinilkloridne) vreče.
PP = Per Protocol Population; ITT = Intent To Treat Population
PP = populacija po protokolu; ITT = populacija z namenom zdravljenja
PP-population
Populacija PP
PP-population
razl.
PP-population
Vsi parcialni
PP-population*
Populacija PP
PP/Aluminium foil blister.
Pretisni omot iz PP/aluminijeve folije.
PP/Aluminium foil blisters in a wallet containing 42 film-coated tablets Xarelto 15 mg and 7 film- coated tablets Xarelto 20 mg (treatment initiation pack).
Pretisni omot PP/aluminij v ovitku, ki vsebuje 42 filmsko obloženih tablet zdravila Xarelto po 15 mg in 7 filmsko obloženih tablet zdravila Xarelto po 20 mg (začetno pakiranje).
PP/Aluminium foil blisters in cartons of 10, 14, 28 or 98 film-coated tablets or perforated unit dose blisters in cartons of 10 x 1, or 100 x 1 or in multipacks containing 100 (10 packs of 10 x 1) film- coated tablets.
Škatla po 10, 14, 28 ali 98 filmsko obloženih tablet v pretisnih omotih iz PP/aluminija ali škatla po 10 x 1 ali 100 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za enkratni odmerek ali v večkratnem pakiranju po 100 filmsko obloženih tablet (10 enot po 10 x 1 filmsko obložena tableta).
PP/Aluminium foil blisters in cartons of 10, 14, 28, 42 or 98 film-coated tablets or perforated unit dose blisters in cartons of 10 x 1, or 100 x 1 or in multipacks containing 100 (10 packs of 10 x 1) film- coated tablets.
Škatla po 10, 14, 28, 42 ali 98 filmsko obloženih tablet v pretisnih omotih iz PP/aluminija ali škatla po 10 x 1 ali 100 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za enkratni odmerek ali v večkratnem pakiranju po 100 filmsko obloženih tablet (10 enot po 10 x 1 filmsko obložena tableta).
PP/Aluminium foil blisters in cartons of 14, 28, 30, 56, 60, 98, 168 or 196 film-coated tablets or perforated unit dose blisters in cartons of 10 x 1 or 100 x 1 or in multipacks containing 100 (10 packs of 10 x 1) film-coated tablets.
Škatla po 14, 28, 30, 56, 60, 98, 168 ali 196 filmsko obloženih tablet v pretisnih omotih iz PP/aluminija ali škatla po 10 x 1 ali 100 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za enkratni odmerek ali v večkratnih pakiranjih, ki vsebujejo 100 (10 enot po 10 x 1) filmsko obloženih tablet.
PP/Aluminium foil blisters or PVC/PVDC/Aluminium foil blisters in cartons of 5, 10 or 30 film- coated tablets or perforated unit dose blisters in cartons of 10 x 1 or 100 x 1 film-coated tablets.
Škatla po 5, 10 ali 30 filmsko obloženih tablet v pretisnih omotih iz PP/aluminija ali PVC/PVDC/aluminija ali škatla po 10 x 1 ali 100 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za enkratni odmerek.
PP/Aluminium foil perforated unit dose blisters in multipacks containing 100 (10 packs of 10 x 1) film-coated tablets.
Večkratno pakiranje vsebuje 100 filmsko obloženih tablet (10 enot po 10 x 1 filmsko obložena tableta) v perforiranih pretisnih omotih za enkratni odmerek iz PP/aluminija.
PPE (ileitis) and swine dysentery
PPE (ileitis) in dizenterija pri prašičih
PPE*, alopecia, rash
PPE*, alopecija, izpuščaj
PPE*, rash
PPE*, izpuščaj
PPS = per protocol set
PPS = bolniki po protokolu (“per protocol set”)
PPSV23 N=395-445
PPSV23 n = 395-445
PR
DR
PR interval
Intervala PR
PR intervals of > 200 msec were seen in 3% of subjects in the active control group (moxifloxacin) and 5% in the placebo arm.
Interval PR > 200 msek so opazili pri 3 % posameznikov, ki so prejemali kontrolno zdravilo (moksifloksacin) in 5 % posameznikov, ki so prejemali placebo.
PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m2/day).
Toksično delovanje na srce in ožilje (podaljšanje intervalov PR in QT) so opazili pri opicah cynomolgus po intravenskem dajanju (100 mg/kg), po večkratnem peroralnem dajanju (1379 mg/m2/dan) pa ne.
Prac-tic 137.5 mg spot-on solution for small dogs
Prac-tic 137,5 mg kožni nanos, raztopina za majhne pse
Prac-tic 275 mg spot-on solution for medium dogs
Prac-tic 275 mg kožni nanos, raztopina za srednje velike pse
Prac-tic 56.25 mg spot-on solution for very small dogs
Prac-tic 56,25 mg kožni nanos, raztopina za zelo majhne pse
Prac-tic 625 mg spot-on solution for large dogs
Prac-tic 625 mg kožni nanos, raztopina za velike pse
Prac-tic should not enter water courses as it may be dangerous for fish and other aquatic organisms.
Prac-tic ne sme priti v vodotoke, ker je lahko nevaren za ribe in druge vodne organizme.
Prac-tic should not enter water courses as this may be dangerous for fish and other aquatic organisms.
Prac-tic ne sme priti v vodotoke, ker je lahko nevaren za ribe in druge vodne organizme.
Prac-tic spot-on for dogs Pyriprole
Prac-tic kožni nanos, raztopina za pse Piriprol
Prac-tic spot-on solution for dogs
Prac-tic kožni nanos, raztopina za pse
Practical details on the preparation of the solution for infusion
Praktične podrobnosti za pripravo raztopine za infundiranje
Practical information for handling and administration of Zalmoxis for the doctor or nurse can be found at the end of this leaflet.
Praktične informacije o ravnanju z zdravilom Zalmoxis in dajanju zdravila Zalmoxis za zdravnike ali medicinske sestre so na koncu tega navodila.
Practical information for handling and administration of ZALTRAP for doctors, nurses and pharmacists when using this medicine, is provided with this leaflet.
To navodilo obsega praktične informacije za ravnanje z zdravilom ZALTRAP in za njegovo dajanje, namenjene zdravnikom, medicinskim sestram in farmacevtom pri uporabi tega zdravila.
Practical information for medical or healthcare professionals on the handling and administration of Zalmoxis.
Praktične informacije za medicinsko ali zdravstveno osebje o ravnanju z zdravilom Zalmoxis in dajanju zdravila
practice
lamotrigina.
Pradaxa (dabigatran etexilate) treatment can be re-initiated 24 hours after administration of Praxbind, if the patient is clinically stable and adequate haemostasis has been achieved.
Zdravljenje z zdravilom Pradaxa (dabigatran eteksilat) lahko ponovno uvedemo 24 ur po dajanju zdravila Praxbind, če je bolnik klinično stabilen in je dosegel ustrezno hemostazo.
Pradaxa 110 mg (only applicable for folding box, not applicable for bottle label)
Pradaxa 110 mg (velja samo za škatlo, ne velja za nalepko na plastenki)
Pradaxa 110 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, cream-coloured body.
Zdravilo Pradaxa 110 mg so trde kapsule z neprozornim, svetlo modrim pokrovčkom in neprozornim telesom kremne barve.
Pradaxa 110 mg hard capsules
Pradaxa 110 mg trde kapsule
Pradaxa 150 mg (only applicable for folding box, not applicable for bottle label)
Pradaxa 150 mg (velja samo za škatlo, ne velja za nalepko na plastenki)
Pradaxa 150 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, cream-coloured body.
Zdravilo Pradaxa 150 mg so trde kapsule z neprozornim, svetlo modrim pokrovčkom in neprozornim telesom kremne barve.
Pradaxa 150 mg hard capsules
Pradaxa 150 mg trde kapsule
Pradaxa 150 mg hard capsules Dabigatran etexilate
Pradaxa 150 mg trde kapsule dabigatran eteksilat
Pradaxa 75 mg (only applicable for folding box, not applicable for bottle label)
PRADAXA 75 mg (velja samo za škatlo, ne velja za nalepko na plastenki)
Pradaxa 75 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, cream-coloured body.
Pradaxa 75 mg so trde kapsule z neprozornim, svetlo modrim pokrovčkom in neprozornim telesom kremne barve.
Pradaxa 75 mg hard capsules
Pradaxa 75 mg trde kapsule
Pradaxa 75 mg hard capsules Dabigatran etexilate
Pradaxa 75 mg trde kapsule dabigatran eteksilat
Pradaxa and these medicines should be taken at the same time.
Zdravilo Pradaxa in ta zdravila je treba jemati hkrati.
Pradaxa and verapamil-containing medicines should be taken at the same time.
Zdravilo Pradaxa in zdravila, ki vsebujejo verapamil, morate jemati skupaj.
Pradaxa can be taken with or without food.
Zdravilo Pradaxa je možno jemati s hrano ali brez hrane.
Pradaxa can be taken with or without food.
Zdravilo Pradaxa lahko jemljete ob jedi ali ne.
Pradaxa can be takenwith or without food.
Zdravilo Pradaxa je možno jemati s hrano ali brez hrane.
Pradaxa contains sunset yellow (E110)
Zdravilo Pradaxa vsebuje sončno rumeno FCF (E110)
Pradaxa does not in general require routine anticoagulant monitoring.
Pri uporabi zdravila Pradaxa na splošno ni potrebno rutinsko spremljati antikoagulacijo.
Pradaxa hard capsules contain the colorant sunset yellow (E110), which may cause allergic reactions.
Zdravilo Pradaxa trde kapsule vsebuje barvilo sončno rumeno FCF (E110), ki lahko povzroči alergijske reakcije.
Pradaxa has no or negligible influence on the ability to drive and use machines.
Zdravilo Pradaxa nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Pradaxa is a blood thinner medicine that lowers the risk of blood clot formation.
Pradaxa je zdravilo za redčenje krvi, ki zmanjša nevarnost nastanka krvnih strdkov.
Pradaxa is a medicine that contains the active substance dabigatran etexilate.
Pradaxa je zdravilo, ki vsebuje zdravilno učinkovino dabigatran eteksilat.
Pradaxa is a medicine which contains the active substance dabigatran etexilate.
Pradaxa je zdravilo, ki vsebuje zdravilno učinkovino dabigatran eteksilat.
Pradaxa is a medicine which is used to reduce the risk of brain or body vessel obstruction by blood clot formation in adult patients with an abnormal heart beat (atrial fibrillation) and additional risk factors.
Pradaxa je zdravilo, ki pri odraslih bolnikih z motnjo srčnega utripa (atrijsko fibrilacijo) in dodatnimi ogrožajočimi dejavniki zmanjša nevarnost, da bi krvni strdek zamašil krvno žilo v možganih ali telesu.
Pradaxa is a medicine which is used to treat blood clots in the veins of your legs and lungs and to prevent blood clots from re-occuring in the vein of your legs and lungs
Pradaxa je zdravilo za zdravljenje krvnih strdkov v venah nog in pljučih ter za preprečevanje ponovnega pojava krvnih strdkov v nožnih venah in pljučih.
Pradaxa is a medicine which is used to treat blood clots in the veins of your legs and lungs and to prevent blood clots from re-occuring in the vein of your legs and lungs
Pradaxa je zdravilo za zdravljenje krvnih strdkov v venah nog in pljučih ter za preprečevanje ponovnega pojava krvnih strdkov v venah nog in pljučih.
Pradaxa is available in packs containing 10 x 1, 30 x 1, 60 x 1 a multipack containing 3 packs of 60 x 1 hard capsules (180 hard capsules) or a multipack containing 2 packs of 50 x 1 hard capsules (100 hard capsules) in aluminium perforated unit dose blisters.
Zdravilo Pradaxa je na voljo v pakiranjih po 10 x 1, 30 x 1, 60 x 1, večkratnih pakiranjih s 3 enotami po 60 x 1 trda kapsula (180 trdih kapsul) ali večkratnih pakiranjih z 2 enotama po 50 x 1 trda kapsula (100 trdih kapsul) v perforiranih aluminijastih pretisnih omotih za enkratni odmerek.
Pradaxa is available in packs containing 10 x 1, 30 x 1, 60 x 1 capsules in aluminium perforated unit dose blisters.
Zdravilo Pradaxa je na voljo v pakiranjih po 10 x 1, 30 x 1 ali 60 x 1 kapsula v perforiranih aluminijastih pretisnih omotih za enkratni odmerek.
Pradaxa is used for the following:
Zdravilo Pradaxa se uporablja v naslednjih primerih:
Pradaxa must also not be used in patients with serious liver problems or patients taking by mouth or injection the medicines ketoconazole and itraconazole (used for fungal infections), ciclosporin (a medicine used to reduce the activity of the immune system) or dronedarone (a medicine to treat a heart problem called atrial fibrillation).
Zdravila Pradaxa ne smejo uporabljati bolniki z resnimi jetrnimi težavami ali bolniki, ki peroralno ali z injiciranjem jemljejo zdravili ketokonazol in itrakonazol (za zdravljenje glivičnih okužb), ciklosporin (zdravilo za zmanjšanje delovanja imunskega sistema) ali dronedaron (zdravilo za zdravljenje težav s srcem, imenovanih atrijska fibrilacija).
Pradaxa should not be used in children and adolescents below 18 years old.
Zdravila Pradaxa ne smemo uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
Pradaxa treatment can be re-initiated 24 hours after administration of Praxabind (idarucizumab), if the patient is clinically stable and adequate haemostasis has been achieved.
Zdravilo Pradaxa lahko bolnik ponovno prejme 24 ur po dajanju zdravila Praxbind (idarucizumab), če je njegovo klinično stanje stabilno in je zagotovljena ustrezna hemostaza.
Pradaxa treatment to parenteral anticoagulant
Zamenjava zdravila Pradaxa s parenteralnim antikoagulantom
Pradaxa treatment to Vitamin K antagonists (VKA)
Prehod z zdravila Pradaxa na antagoniste vitamina K
Pradaxa was as effective as enoxaparin in preventing the formation of blood clots or death.
Zdravilo Pradaxa se je pri preprečevanju nastanka krvnih strdkov ali smrti izkazalo za enako učinkovito kot enoksaparin.
Pradaxa will need to be stopped temporarily due to an increased bleeding risk during and shortly after an operation.
Zdravilo Pradaxa bo treba začasno ukiniti zaradi povečane nevarnosti krvavitve med operacijo in krajši čas po njej.
Pradaxa, which is taken by mouth, has the advantage of being more convenient for patients.
Prednost zdravila Pradaxa, ki se jemlje peroralno, je v tem, da je prikladnejše za bolnike.
Pradaxa® can be taken with or without food.
Zdravilo Pradaxa lahko jemljete med jedjo ali brez.
Pradaxa® Dabigatran etexilate
Pradaxa® dabigatran eteksilat
Pradaxa® Information for Healthcare Professionals
Pradaxa®, informacija za zdravstvene delavce
Pradaxa® Information for Patients
Pradaxa®, informacija za bolnike
Pradaxa® is an oral anticoagulant acting by direct thrombin inhibition.
Zdravilo Pradaxa® (dabigatran eteksilat) je peroralni antikoagulant, ki deluje tako, da neposredno zavira trombin.
Pradaxa® is dialyzable.
Zdravilo Pradaxa® se med dializo izloča.
Pradaxa® makes your blood less “sticky”, prevents clot formation and reduces your risk of suffering from a stroke or other complications.
Zdravilo Pradaxa® napravi kri manj 'lepljivo', prepreči nastanek krvnih strdkov in zmanjša tveganje za možgansko kap ali druge zaplete.